Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04046497 · ClinicalTrials.gov registry record · Phase 4
Artificial Intelligence to Measure Adherence to Oral Medication
A Phase 4 study of First Episode Psychosis, sponsored by Northwell Health.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
- 5
- Study locations
NCT04046497: Recruiting Phase 4 study of First Episode Psychosis, sponsored by Northwell Health.
NCT04046497 is a Phase 4 study of First Episode Psychosis that is actively recruiting participants, run by Northwell Health. The registered enrollment target is 200 participants, below the 6,408-participant average among 8 other First Episode Psychosis trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04046497, a Phase 4 study of First Episode Psychosis, is actively recruiting participants, sponsored by Northwell Health.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
- 5
- Study locations
Study Summary
The aims of this project is to use an artificial intelligence (AI) smartphone app to provide support for medication adherence by patients with first episode psychosis.
Primary Outcome
Provides participant utilization of psychiatric ER visits or psychiatric hospitalization
Conditions Studied
Interventions
- OTHER Usual Care
- OTHER Smartphone App
Study Locations (5)
Michigan
- InterAct - Grand Rapids
- InterAct of Michigan - Kalamazoo
Oklahoma
- Red Rock - Oklahoma City
- Family and Children's Services - Tulsa
Florida
- Citrus Health - Hialeah
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2020-11-20 |
| Est. Completion | 2024-12-31 |
| Phase | Phase 4 |
What NCT04046497 shows while recruiting
NCT04046497 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 6,408-participant average among 8 other First Episode Psychosis trials with a reported enrollment target (97% lower).
The record links to 1 condition, with First Episode Psychosis appearing as the primary indexed condition, and to 2 interventions - of which Usual Care is the first listed.
NCT04046497 lists 5 locations in 3 states (Michigan, Oklahoma, Florida).
Frequently Asked Questions
What is clinical trial NCT04046497 about?
NCT04046497 is a clinical study titled "Artificial Intelligence to Measure Adherence to Oral Medication". The aims of this project is to use an artificial intelligence (AI) smartphone app to provide support for medication adherence by patients with first episode psychosis.
What is the current status of trial NCT04046497?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2020-11-20. Estimated completion is 2024-12-31.
What conditions does trial NCT04046497 study?
This clinical trial studies the following conditions: First Episode Psychosis.
What interventions are being tested in trial NCT04046497?
The interventions under investigation include: Usual Care (OTHER), Smartphone App (OTHER).
Who is sponsoring clinical trial NCT04046497?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04046497 being conducted?
This trial has 5 study locations across Florida, Michigan, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for First Episode Psychosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04046497's enrollment target sits among peer trials
200 5th of 8 higher than 4 of 8 other First Episode Psychosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other First Episode Psychosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Disengagement in CSC: Identifying Those at Risk and Addressing Their Needs
RECRUITING · Phase 4
-
Pilot RCT of Self-stigma Treatment for First Episode Psychosis
RECRUITING · NA
-
Digital Strategies to Advance Help-Seeking Aim 1 and 2
RECRUITING
-
Early-Phase Schizophrenia: Practice-based Research to Improve Outcomes
RECRUITING
-
Digital Strategies to Advance Help-Seeking - Aim 3
RECRUITING · NA
-
Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI